Most discussions of Wegovy focus on weight. The cardiovascular angle gets less attention but matters considerably. After the SELECT trial results, Wegovy became the first weight management medication approved specifically to reduce the risk of heart attack, stroke, and cardiovascular death.

This is not a minor footnote. For many patients with excess weight and existing cardiovascular disease, the heart benefit is as significant as the weight benefit.

What The SELECT Trial Showed

SELECT enrolled over 17,000 adults with established cardiovascular disease (previous heart attack, stroke, or peripheral artery disease) and a BMI of 27 or higher. They did not have diabetes at enrolment. Half received Wegovy 2.4 mg weekly, half received placebo. Both groups received standard cardiovascular care.

Over an average of three years of follow up:

  • The combined risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke was reduced by 20 percent in the Wegovy group compared to placebo
  • The benefit appeared within the first six months, before maximal weight loss had occurred
  • The benefit persisted throughout the trial
  • Weight loss in the Wegovy group averaged around 10 percent (lower than in non-diabetic obesity trials because the population was different)

This was the trial that earned Wegovy the cardiovascular indication.

What This Means In South Africa

SAHPRA registration includes the cardiovascular indication. Wegovy can be prescribed specifically to reduce major adverse cardiovascular events in adults with:

  • Established cardiovascular disease (previous heart attack, stroke, peripheral artery disease, or significant coronary disease), and
  • A BMI of 27 kg/m² or higher

This is separate from the weight management indication, although the same medication and dose schedule apply.

Why It Works For The Heart

Several mechanisms are thought to contribute:

Weight reduction itself

Weight loss reduces strain on the cardiovascular system, lowers blood pressure, improves lipid profile, and reduces insulin resistance. Some of the cardiovascular benefit is explained by this.

Blood pressure reduction

Wegovy reduces both systolic and diastolic blood pressure by a few points on average. Over years, this translates into reduced cardiovascular risk.

Improved blood sugar

Even in non-diabetics, semaglutide lowers blood sugar slightly and reduces insulin resistance. Both improve cardiovascular risk.

Direct effects on inflammation

Inflammation drives atherosclerosis. GLP-1 receptors are present on inflammatory cells, and semaglutide appears to reduce inflammatory markers. Some of the cardiovascular benefit may come through this pathway.

Possible direct effects on blood vessels

GLP-1 receptors are also present on blood vessel walls. Whether semaglutide acts directly on these to improve vascular function is still being studied.

The earlier than expected onset of cardiovascular benefit in SELECT (before significant weight loss) supports the view that some of the effect is independent of weight.

Discuss Cardiovascular Indications With A Doctor

If you have a history of cardiovascular disease, an online consultation can review whether Wegovy fits your specific risk profile.

Start Consultation

Who This Applies To

The cardiovascular indication has specific criteria. It is not for general heart protection in people without established disease. It is for people who have already had a major cardiovascular event or have documented atherosclerotic cardiovascular disease, and who also carry excess weight.

People who fit this profile often:

  • Have had a previous heart attack or stroke
  • Have had cardiac stents placed or bypass surgery
  • Have peripheral arterial disease
  • Have significant coronary artery disease documented on imaging
  • Carry BMI of 27 or higher

For these people, the conversation about Wegovy is no longer just about weight. It is about reducing the probability of the next cardiovascular event.

What About People Without Established Cardiovascular Disease

The cardiovascular benefit in primary prevention (people with risk factors but no established disease) is less well established. The general principle holds (weight loss, blood pressure reduction, glucose improvement all reduce future risk) but specific trials have not been done in that population.

For most people considering Wegovy for weight management, the cardiovascular benefit is a positive secondary effect rather than the primary indication.

Integration With Other Cardiovascular Medications

Wegovy is added alongside standard cardiovascular medications, not as a replacement. People on statins, antihypertensives, antiplatelets, and beta blockers continue these. Dose adjustments may be needed over time as blood pressure and blood sugar respond to the medication and weight loss.

One specific note: people on insulin or sulfonylureas for diabetes need dose adjustment when starting Wegovy to avoid hypoglycaemia. The treating doctor handles this.

What This Does Not Replace

Standard cardiovascular care continues:

  • Stopping smoking remains the single biggest cardiovascular risk reduction
  • Statins for cholesterol
  • Antihypertensives for blood pressure
  • Antiplatelets after a previous event
  • Cardiac rehabilitation after a major event
  • Regular cardiology follow up

Wegovy adds to this picture for eligible patients. It does not subtract from any of it.

Related Reading

Frequently Asked

In the SELECT trial in people with established cardiovascular disease and a BMI of 27 or more, Wegovy reduced the combined risk of cardiovascular death, heart attack, and stroke by 20 percent compared to placebo over an average of three years.

Partially, but not entirely. The cardiovascular benefit appeared earlier and was larger than what weight loss alone would predict. The mechanism is thought to be multifactorial: weight, blood pressure, blood sugar, inflammation, and possibly direct effects on blood vessels.

The cardiovascular indication requires a BMI of 27 or more and established cardiovascular disease. People with normal BMI are not eligible regardless of cardiovascular history.

The SELECT trial studied secondary prevention (people who already had cardiovascular disease). The benefit in people without established cardiovascular disease is being studied but is less well established.